B. Metzler seel. Sohn & Co. Holding AG Makes New Investment in Catalent, Inc. (NYSE:CTLT)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Catalent, Inc. (NYSE:CTLT) in the third quarter, HoldingsChannel reports. The fund acquired 4,554 shares of the company’s stock, valued at approximately $276,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CTLT. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent in the 2nd quarter valued at about $42,000. Sentry Investment Management LLC acquired a new position in Catalent during the third quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC raised its holdings in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after purchasing an additional 305 shares during the period. GAMMA Investing LLC raised its stake in Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after buying an additional 212 shares during the period. Finally, Intact Investment Management Inc. acquired a new stake in shares of Catalent during the third quarter worth about $73,000.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 over the last 90 days. 0.31% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a research report on Friday. Robert W. Baird reissued a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. Based on data from MarketBeat.com, Catalent currently has an average rating of “Hold” and an average target price of $63.40.

Catalent Price Performance

NYSE:CTLT opened at $61.24 on Tuesday. The stock has a market capitalization of $11.12 billion, a PE ratio of -27.10, a P/E/G ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.50. The firm has a fifty day simple moving average of $59.81 and a 200 day simple moving average of $58.32. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business’s revenue was up 4.2% on a year-over-year basis. During the same period last year, the business earned ($0.10) EPS. On average, research analysts expect that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.